Cargando…

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

Detalles Bibliográficos
Autores principales:	Fiorelli, Alfonso, Vitiello, Fabiana, Morgillo, Floriana, Santagata, Mario, Spuntarelli, Chiara, Di Domenico, Marina, Santini, Mario, Bianco, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2019
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799010/ https://www.ncbi.nlm.nih.gov/pubmed/35117144 http://dx.doi.org/10.21037/tcr.2019.06.28

Ejemplares similares

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures
por: Della Corte, Carminia Maria, et al.
Publicado: (2019)

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
por: Liu, Qiao, et al.
Publicado: (2022)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression
por: Takumida, Hiroshi, et al.
Publicado: (2021)

Real-World Data Analysis of Pembrolizumab Monotherapy for NSCLC Using Japanese Postmarketing All-Case Surveillance Data
por: Terai, Hideki, et al.
Publicado: (2022)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
por: Velcheti, Vamsidhar, et al.
Publicado: (2022)

Is pembrolizumab monotherapy the optimal treatment for elderly patients with PD-L1 positive advanced non-small cell lung cancer?
por: Mienko, Fiona, et al.
Publicado: (2020)

Commentary: Ticagrelor monotherapy—Not for CABG?
por: Sandner, Sigrid, et al.
Publicado: (2022)

Descending necrotizing mediastinitis in the elderly patients
por: Mazzella, Antonio, et al.
Publicado: (2016)

Small bowel metastasis from pancreatic cancer in a long-term survival patient with synchronous advanced malignant pleural mesothelioma: A case report and literature review
por: Fasano, Morena, et al.
Publicado: (2016)

Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
por: Jung, Hyun Ae, et al.
Publicado: (2022)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
por: Della Corte, Carminia Maria, et al.
Publicado: (2022)

Pembrolizumab—the “KEY” to an evolving landscape in treatment of squamous non-small cell lung cancer (NSCLC)
por: Yellala, Amulya, et al.
Publicado: (2020)

Keynote 42: Pembrolizumab, PD-L1, and where to draw the line
por: Isaacs, James, et al.
Publicado: (2020)

Pulmonary pleomorphic carcinoma with pembrolizumab monotherapy
por: Chang, Hao‐Chun, et al.
Publicado: (2020)

AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma
por: Zito Marino, Federica, et al.
Publicado: (2022)

New Trends in Precision Medicine: A Pilot Study of Pure Light Scattering Analysis as a Useful Tool for Non-Small Cell Lung Cancer (NSCLC) Diagnosis
por: Rossi, Domenico, et al.
Publicado: (2021)

Into the Clinic With Nivolumab and Pembrolizumab
por: Shu, Catherine A., et al.
Publicado: (2016)

Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers
por: Vicidomini, Giovanni, et al.
Publicado: (2020)

ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
por: Fujimoto, Daichi, et al.
Publicado: (2021)

First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan
por: Goto, Yasushi, et al.
Publicado: (2022)

Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
por: Hearon, Bernard F., et al.
Publicado: (2020)

Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy
por: Rittberg, Rebekah, et al.
Publicado: (2023)

Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
por: Catanese, Silvia, et al.
Publicado: (2020)

Cost‐effectiveness analysis of pembrolizumab plus chemotherapy with PD‐L1 test for the first‐line treatment of NSCLC
por: Wan, Ning, et al.
Publicado: (2020)

Pembrolizumab Alone or Combined With Chemotherapy in Advanced NSCLC With PD-L1 ≥50%: Results of a Retrospective Study
por: Chen, Ya, et al.
Publicado: (2021)

Outcome differences between PD-1/PD-L1 inhibitors-based monotherapy and combination treatments in NSCLC with brain metastases
por: Wang, Haowei, et al.
Publicado: (2023)

Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
por: Matsubara, Taichi, et al.
Publicado: (2021)

Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
por: Rotte, Anand
Publicado: (2023)

A Trimodality, Four-Step Treatment including Chemotherapy, Pleurectomy/Decortication and Radiotherapy in Early-Stage Malignant Pleural Mesothelioma: A Single-Institution Retrospective Case Series Study
por: Vicidomini, Giovanni, et al.
Publicado: (2021)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
por: Krukowska, Kinga, et al.
Publicado: (2020)

The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management
por: Denault, Marie-Helene, et al.
Publicado: (2023)

Implementing Keytruda/Pembrolizumab Testing in Clinical Practice
por: Ratner, Dmitry, et al.
Publicado: (2018)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

The use of 3D printing model as tool for planning endoscopic treatment of benign airway stenosis
por: Natale, Giovanni, et al.
Publicado: (2020)

Correlation of peripheral blood biomarkers with clinical outcomes in NSCLC patients with high PD-L1 expression treated with pembrolizumab
por: Sánchez-Gastaldo, Amparo, et al.
Publicado: (2021)

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
por: Troiani, Teresa, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_fd4uv9ukv0cnrcva2l6d7ak53a